GUANGZHOU, China, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Fanhua Inc. (Nasdaq: FANH) (the “Company” or “FANHUA”), a leading independent technology-driven financial services provider in China, today announced that it, through its wholly-owned subsidiary Fanhua BluePlus Health Management Co., Ltd. (“Fanhua BluePlus”) has recently signed a strategic cooperation agreement with Shanghai Biotecan Pharmaceuticals Co. Ltd. (“Biotecan”).
Pursuant to the strategic cooperation agreement, Fanhua BluePlus and Biotecan will leverage their respective resources and service strengths to collaborate on cutting-edge medical testing, health management, cell therapy, and other modern high-end medical and health management services.
Commenting on the agreement, Chief Executive Officer of Fanhua BluePlus Mr. Qiao Yu said, “We are excited about our strategic cooperation with Biotecan, a pioneer in clinical molecular diagnostics and biomedicine in China. It fully demonstrates our commitment to meeting customers' needs for a high-quality life. We look forward to working with Biotecan to safeguard our customers' health and well-being. As a one-stop health and wellness service platform provider, we will continue to seek partnership with top biopharmaceutical enterprises to connect health and wellness service providers with biopharmaceutical enterprises and to provide more clients with comprehensive healthcare solutions.”
About Fanhua BluePlus
Fanhua BluePlus Health Management Co., Ltd., a one-stop wellness service platform under Fanhua Inc., was established in 2010 and has been deeply involved in the industry for 13 years. With partnerships with over 110 top domestic medical, wellness, and financial institutions, Fanhua BluePlus provides health and wellness services to more than 50,000 clients annually. The platform offers a comprehensive product matrix that fully addresses clients’ needs across “prevention, medical care, nursing, health maintenance, and elder care”.
About Biotecan
Established in 2008, Shanghai Biotecan Pharmaceuticals Co. Ltd. has over 20 subsidiaries and is a pioneer in clinical molecular diagnostics in China. It has partnered with more than 120 Grade-III Class-A hospitals nationwide to establish molecular medical centers, providing precision medical molecular diagnostics and clinical research services to over 1,000 hospitals. The in-hospital laboratory network created by Biotecan offers more than 2,000 precision medical services covering oncology, chronic diseases, maternal and child health, infectious diseases, intestinal microbiome diseases, and general health exams. Over 200 million Biotecan’s visitors receive outpatient and emergency treatments per year.
About Fanhua
Established in Guangzhou in 1998 and listed on NASDAQ in 2007 (Nasdaq: FANH), Fanhua is a leading independent financial services provider in China with strong technology capabilities and a commitment to empowering financial advisors and fostering sustained value creation for customers.
Our mission revolves around creating an inclusive and collaborative platform for independent financial advisors, as well as various insurance/financial sales organizations, enabling our partners to optimize their practices by offering them end-to-end business solutions spanning compliance, technology, products, services, operations, capital flow, and professional training.
Leveraging advanced technology, artificial intelligence, and data-driven insights, Fanhua is at the forefront of revolutionizing financial services delivery, accelerating digital transformation, and driving industry growth.
With a comprehensive approach to financial services, we connect millions of Chinese families with various financial institutions and service providers, offering a diverse range of opportunities and personalized solutions for insurance protection, retirement planning, health management, asset management, and family governance services, covering the full lifecycle of our customers’ needs.
Forward-looking Statements
This press release contains statements of a forward-looking nature. These statements, including the statements relating to the Company’s future financial and operating results, are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as "will", "expects", "believes", "anticipates", "intends", "estimates" and similar statements. Among other things, management’s quotations contain forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about Fanhua and the industry. Potential risks and uncertainties include, but are not limited to, those relating to its ability to attract and retain productive agents, especially entrepreneurial agents, its ability to maintain existing and develop new business relationships with insurance companies, its ability to execute its growth strategy, its ability to adapt to the evolving regulatory environment in the Chinese insurance industry, its ability to compete effectively against its competitors, quarterly variations in its operating results caused by factors beyond its control and macroeconomic conditions in China and their potential impact on the sales of insurance products. Except as otherwise indicated, all information provided in this press release speaks as of the date hereof, and Fanhua undertakes no obligation to update any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although Fanhua believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. Further information regarding risks and uncertainties faced by Fanhua is included in Fanhua’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.
For more information, please contact:
Fanhua Inc.
Investor Relations
Tel: +86 (20) 8388-3191
Email: ir@fanhgroup.com
Source: Fanhua Inc.
